Merrill Lynch & Co. Inc. disclosed Bayer (ETR:BAYN), hiking its stock price target to 105.00EUR earlier today
- Updated: September 19, 2016
Yesterday Bayer (ETR:BAYN) traded 0.00% even at 91.58EUR. BAYN’s 50-day average is 0.04EUR and its two hundred day moving average is 0.03EUR. The last stock price close is up 2.57% relative to the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. Volume of trade was was down over the average, with 0 shares of BAYN changing hands under the typical 215 shares..
In an issued report on 9/20/2016 Merrill Lynch & Co. Inc. upped the target price of Bayer (ETR:BAYN) from 0EUR to 105EUR stating a possible upsideof 0.15%.
On Monday September 19 2016, Merrill Lynch & Co. Inc. reported on Bayer(ETR:BAYN) upped the target price from 0.00EUR to 105.00EUR. At the time, this suggested an upside of 0.15%.
See Chart Below:
Bayer has a 52 week low of 0.03EUR and a one-year high of 0.04EUR and has a market cap of 0.0 EUR.
Brief Synopsis On Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.